• SHC-1 Inhibition Elevates CFTR Surface Levels in Epithelial

  2026-04-29

  This study systematically investigates the role of SHC-1 inhibition in increasing plasma membrane CFTR abundance across diverse epithelial cell models. By dissecting the MAPK/SHC-1 signaling axis, the authors highlight cell-type-specific responses and reveal mechanistic insights relevant to cystic fibrosis and secretory epithelial disease research.

• MLKL Polymerization Drives Lysosomal Cathepsin B Release in

  2026-04-28

  This study uncovers how MLKL polymerization at lysosomal membranes causes membrane permeabilization and triggers the release of cathepsin B, a key event in necroptosis execution. The findings clarify the sequence of cellular events in necroptosis and highlight the protective effects of cathepsin B inhibition, guiding future research on regulated cell death.

• Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO): Practica

  2026-04-28

  The Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) addresses protein degradation during cell and tissue extraction, especially for workflows involving mass spectrometry. It is unsuitable for protocols requiring metalloproteinase inhibition unless EDTA is supplemented and should not be used in non-aqueous solvents.

• Z-VAD-FMK for Apoptosis Inhibition: Applied Workflows & Tips

  2026-04-27

  Z-VAD-FMK empowers researchers to achieve precise apoptosis inhibition and robust caspase pathway analysis across diverse cell models. This guide distills experimental workflows, troubleshooting strategies, and recent mechanistic insights, ensuring reliable results in apoptosis research and beyond.

• Protease Inhibitor Cocktail EDTA-Free: Enhancing Protein Int

  2026-04-27

  The Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) empowers researchers to achieve uncompromised protein extraction, even in cation-sensitive workflows. This article bridges recent innovations in mitocytosis modulation with practical, stepwise protocols and troubleshooting insights for advanced protein analysis.

• Annexin V-FITC/7-AAD Apoptosis Kit: Technical Workflow Guide

  2026-04-26

  The Annexin V-FITC/7-AAD Apoptosis Kit enables precise, rapid identification of apoptotic and necrotic cells for researchers conducting cell viability and cytotoxicity assays. It should be applied in established phosphatidylserine binding workflows using fluorescence microscopy or flow cytometry, but is not intended for pathway elucidation or applications outside standardized cell death analysis.

• Remdesivir (GS-5734): Protocols and Troubleshooting for RNA

  2026-04-25

  Remdesivir (GS-5734) is a validated, broad-spectrum RNA virus inhibitor, uniquely enabling robust viral suppression in coronavirus and Ebola research. This article translates benchmark data and experimental insights into practical workflows, troubleshooting, and comparative perspectives for advanced antiviral discovery.

• Meropenem Trihydrate: Unlocking Resistance Pathways in Trans

  2026-04-24

  Explore how Meropenem trihydrate, a broad-spectrum carbapenem antibiotic, drives breakthrough insights in resistance mechanism mapping, experimental design, and translational strategy. Drawing upon state-of-the-art LC-MS/MS metabolomics, this thought-leadership article connects molecular action to clinical innovation, offering evidence-based guidance for infectious disease researchers.

• Staurosporine: Broad-Spectrum Serine/Threonine Kinase Inhibi

  2026-04-24

  Staurosporine is a potent broad-spectrum serine/threonine protein kinase inhibitor with nanomolar activity against multiple PKC isoforms. It is widely used to induce apoptosis in cancer cell lines and to dissect kinase signaling pathways. Its validated anti-angiogenic effects are linked to inhibition of VEGF receptor autophosphorylation.

• CAPE Inhibits C. difficile Toxins and Modulates Gut Microbio

  2026-04-23

  Guo et al. (2025) identify caffeic acid phenethyl ester (CAPE) as a direct inhibitor of the major toxin TcdB produced by Clostridioides difficile, demonstrating its therapeutic potential in infection models. Their work also uncovers CAPE's role in restoring gut microbiota diversity, offering a dual strategy for combating antibiotic-associated C. difficile infection.

• Omeprazole (A2845): Technical Guide for Gastric Acid Researc

  2026-04-23

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor optimized for research on gastric acid secretion and antiulcer activity. It should be used strictly within controlled laboratory workflows and is not intended for diagnostic or clinical applications.

• H-89: Applied Use-Cases in cAMP-Dependent Protein Kinase Inh

  2026-04-22

  H-89 unlocks precise modulation of cAMP signaling, empowering researchers to decode PKA-driven cellular processes from osteogenesis to apoptosis. This guide distills advanced workflow strategies, troubleshooting insights, and protocol optimizations, leveraging evidence from recent metabolic bone research. Discover how APExBIO’s H-89 delivers reproducibility and selectivity in high-impact applications.

• Partial BACE Inhibition Reduces Amyloid Beta Without Synapti

  2026-04-22

  Satir et al. (2020) demonstrated that partial inhibition of BACE1, leading to less than 50% reduction in amyloid-beta (Aβ) secretion, does not impair synaptic transmission in primary neuronal cultures. This finding refines therapeutic strategies for Alzheimer's disease by highlighting a safety window for BACE inhibitor use, supporting amyloid reduction without compromising neuronal function.

• Fumagillin as a Methionine Aminopeptidase-2 Inhibitor: Appli

  2026-04-21

  Fumagillin's unique action as a methionine aminopeptidase-2 inhibitor enables precise dissection of angiogenesis and targeted antiparasitic studies. This article translates recent evidence into actionable protocols, troubleshooting strategies, and comparative insights for researchers seeking reproducible results in cancer and aquaculture applications.

• Meropenem: β-Lactam Antibiotic Carbapenem for Resistance Mod

  2026-04-21

  Meropenem is an ultra-broad-spectrum β-lactam antibiotic carbapenem with robust activity against both Gram-negative and Gram-positive bacteria. It targets penicillin-binding proteins to inhibit bacterial cell wall synthesis, making it essential in research on multidrug resistance and septicemia models. This article provides atomic, verifiable data on Meropenem’s mechanisms, resistance benchmarks, and protocol integration.

437 records 19/30 page Previous Next First page 上5页 1617181920 下5页 Last page